Literature DB >> 7710373

Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype.

B T Hyman1, H L West, G W Rebeck, F Lai, D M Mann.   

Abstract

BACKGROUND: The neuropathological changes of Alzheimer's disease occur universally in individuals with Down's syndrome as they reach middle age and worsen with increasing age. Thus, evaluation of patients of various ages with Down's syndrome allows one to construct a life history of the development of neuropathological changes associated with Alzheimer's disease at various points in the disease process.
METHODS: We have used semiquantitative scales and quantitative computerized image analysis techniques to analyze the characteristics of neurofibrillary tangle formation and A beta amyloid deposition in the hippocampal formation and inferior temporal gyrus in 36 individuals with Down's syndrome ranging in age from 4 to 73 years.
RESULTS: Neurofibrillary tangles occur in a hierarchical distribution in a circumscribed set of neuronal fields, affecting the entorhinal cortex, area CA1/subiculum, then other hippocampal subfields. Although amyloid deposition occurs more evenly in a more widespread distribution, it also accumulates over the years 30 to 50. Surprisingly, examination of the patients available older than 50 years showed no trend toward continued increased deposition of amyloid. Within this group, however, individuals who had inherited the apolipoprotein E (Apo E) epsilon 4 genotype contained more than twice the amyloid burden of individuals who did not inherit the Apo E epsilon 4 genotype. COMMENT: This large series of cases confirms earlier observations that had suggested early vulnerability of entorhinal cortex and CA1/subiculum for neurofibrillary tangles and a more widespread but specific topography of A beta deposition. Moreover, it demonstrates quantitatively that the lesions increase to a certain level and then apparently reach a plateau. The level of amyloid deposition in Down's syndrome is higher than in sporadic Alzheimer's disease. Inheritance of the Apo E epsilon 4 genotype appears to be an additional (independent) risk factor for developing higher levels of amyloid accumulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7710373     DOI: 10.1001/archneur.1995.00540280059019

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  34 in total

1.  Event-related potential index of age-related differences in memory processes in adults with Down syndrome.

Authors:  Alexandra P Key; Elisabeth M Dykens
Journal:  Neurobiol Aging       Date:  2013-08-29       Impact factor: 4.673

2.  Tau-amyloid interactions in the rTgTauEC model of early Alzheimer's disease suggest amyloid-induced disruption of axonal projections and exacerbated axonal pathology.

Authors:  Amy M Pooler; Manuela Polydoro; Susanne K Wegmann; Rose Pitstick; Kevin R Kay; Laura Sanchez; George A Carlson; Teresa Gomez-Isla; Mark W Albers; Tara L Spires-Jones; Bradley T Hyman
Journal:  J Comp Neurol       Date:  2013-12-15       Impact factor: 3.215

3.  Alzheimer's Disease in Adults with Down Syndrome.

Authors:  Warren B Zigman; Darlynne A Devenny; Sharon J Krinsky-McHale; Edmund C Jenkins; Tiina K Urv; Jerzy Wegiel; Nicole Schupf; Wayne Silverman
Journal:  Int Rev Res Ment Retard       Date:  2008-01-01

Review 4.  Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease.

Authors:  Greg M Cole; Sally A Frautschy
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

Review 5.  Improving Memory and Cognition in Individuals with Down Syndrome.

Authors:  Michael S Rafii
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

6.  Comparative quantitative study of 'signature' pathological lesions in the hippocampus and adjacent gyri of 12 neurodegenerative disorders.

Authors:  Richard A Armstrong; Nigel J Cairns
Journal:  J Neural Transm (Vienna)       Date:  2015-05-01       Impact factor: 3.575

7.  Hemizygous minipigs produced by random gene insertion and handmade cloning express the Alzheimer's disease-causing dominant mutation APPsw.

Authors:  Peter M Kragh; Anders Lade Nielsen; Juan Li; Yutao Du; Lin Lin; Mette Schmidt; Ingrid Brück Bøgh; Ida E Holm; Jannik E Jakobsen; Marianne G Johansen; Stig Purup; Lars Bolund; Gábor Vajta; Arne Lund Jørgensen
Journal:  Transgenic Res       Date:  2009-01-29       Impact factor: 2.788

Review 8.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

Review 9.  Impact of amyloid imaging on drug development in Alzheimer's disease.

Authors:  Chester A Mathis; Brian J Lopresti; William E Klunk
Journal:  Nucl Med Biol       Date:  2007-09-04       Impact factor: 2.408

10.  Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.

Authors:  Clayton A Wiley; Brian J Lopresti; Sriram Venneti; Julie Price; William E Klunk; Steven T DeKosky; Chester A Mathis
Journal:  Arch Neurol       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.